鉅子生物(02367.HK):根據一般授權配售現有股份及補足認購新股份 募資約23億港元
格隆匯4月17日丨鉅子生物(02367.HK)發佈公吿,2025年4月16日,公司、補足賣方(即Juzi Holding Co., Ltd)及聯席賬簿管理人(即高盛、中金公司及匯豐)訂立配售及認購協議,據此,(i)補足賣方已同意出售,而聯席賬簿管理人個別同意作為補足賣方代理盡最大努力促使承配人按每股66.65港元的價格購買補足賣方所持有的3500萬股股份,及(ii)補足賣方有條件同意認購,而公司有條件同意按相等於配售價的價格發行有關數目的新股份(相等於賣方配售項下實際配售的股份)。
配售股份數目應與認購股份數目相同,約佔本公吿日期公司已發行股份數目的約3.38%,及經配發及發行認購股份擴大後的股份數目的約3.27%。配售及認購所得款項總額預期合共約為23.33億港元,而配售及認購所得款項淨額預期合共約為22.94億港元。配售及認購所得款項淨額擬用於(i)核心業務的發展及生態圈佈局,包括但不限於品牌推廣、市場營銷、品類擴展、海外業務及研發投入;及(ii)補充流動資金及作一般企業用途。
本次配售及認購募集資金到位後,將增強集團的資金實力、市場競爭力及綜合實力,促進集團長遠健康及可持續發展。配售及認購亦將透過吸引若干高品質機構投資者進一步豐富公司股東基礎,並且通過配售進一步加強股份流動性。認購股份將根據一般授權配發及發行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.